Amgen Price Target Raised to $410.00/Share From $359.00 by Morgan Stanley

What happened

Morgan Stanley raised its price target for Amgen to $410.00 per share from $359.00 per share. The firm maintained its Equal-Weight rating, according to the supplied ratings-action report.

Confirmed

Global impact / market context

A higher price target signals that Morgan Stanley sees more potential value in Amgen shares than its previous target implied, but keeping the Equal-Weight rating indicates no change in its stated relative stance. The report gives no reasons or estimates explaining the revised target.

Analyst inference

The supplied item reports an analyst forecast change, not a change to Amgen’s business results, drug outlook, or capital spending. Any effect on investor positioning would depend on how investors weigh the higher target against the unchanged rating and other information not provided here.

Analyst inference

What to watch

1. Look for a stated explanation of Morgan Stanley’s higher target, such as revised assumptions about Amgen’s revenue, costs, or future cash available; none is included here. Analyst inference
2. Check whether Morgan Stanley changes its Equal-Weight rating in a later update; the supplied report says the rating was maintained, not upgraded or lowered. Confirmed
3. Compare future company results and outlook with the assumptions behind the new target, if those assumptions are disclosed, to assess whether expected business performance supports it. Analyst inference

Evidence

• Original source link unavailable